Phibro Animal Health | PAHC - 销售和管理费用

金融业

USD

USD 1.45B

现金及等价物

USD 54.93M

USD 240.42M

USD 894.07M

USD 281.87M

USD 474.17M

股息收益率

1.29

USD 54.99M

USD 68.1M

1.92K

EPS每股收益

USD 0.78

股本和储备

USD 361.83M

USD 133.5M

债务利息支出

USD 11.91M

USD 0.08

USD 597.69M

USD 1.29B

USD 27.46M

USD 361.83M

USD 54.99M

普通股股本

USD 40.48M

13.82

USD 38.63M

USD 373.91M

销售和管理费用

USD 78.32M

USD 539.7M

贸易债权人

USD 129.64M

应收帐款人

USD 215.87M

	销售和管理费用	更改		日
Align Technology	USD 465.34M		23.67M	2026-03
ANI Pharmaceuticals	USD 73.66M		9.14M	2026-03
Aurora Cannabis	CAD 40.62M		1.17M	2025-12
Bristol-Myers Squibb	USD 1.62B		564M	2026-03
Canopy Growth	CAD 28.9M		636K	2025-12
Corcept Therapeutics	USD 128.04M		13.3M	2026-03
Eli Lilly	USD 2.93B		198M	2026-03
Henry Schein	USD 809M		1000K	2026-03
Idexx Laboratories	USD 299.85M		24.18M	2026-03
Knight Therapeutics	CAD 35.45M		4.43M	2025-12
Merck	USD 2.67B		180M	2026-03
Nektar Therapeutics	USD 10.17M		10.17M	2025-12
Pacira	USD 83.88M		7.99M	2026-03
Phibro Animal Health	USD 78.32M		10.24M	2025-12
Prestige Brands	USD 30.28M		606K	2026-03
Supernus Pharmaceuticals	USD 118.23M		4.16M	2026-03
Zoetis	USD 588M		31M	2026-03